Astellas Names VP, Government
Affairs and Policy
Astellas has appointed Joseph Devaney as VP, government affairs and policy, Americas. Based in Astellas’ Washington, D.C., office, Mr. Devaney is responsible for leading Astellas’ government Affairs and Policy team and developing, communicating, and implementing the company’s federal and state government strategies, engagement activities, and policy development across all functional areas. He also serves as a key representative of Astellas to policy decision leaders and trade organizations.
Mr. Devaney joins Astellas after 20 years at Sanofi and its predecessor companies, where he held roles of increasing responsibility in public policy and market access, including most recently the role of VP of federal and state relations.
Leading BioSciences Appoints CEO
Leading BioSciences, a clinical-stage biopharmaceutical company advancing programs that address medical conditions resulting from a breakdown of the mucosal barrier, has appointed Greg Doyle as CEO. Mr. Doyle, a long-standing member of the executive management team and board of directors, served as chief operations officer and chief financial officer.
Dr. Glenn Nedwin
Second Genome Appoints
CEO and President
Second Genome, a privately held biopharmaceutical company developing novel medicines through innovative microbiome science, has appointed Glenn Nedwin, Ph.D., as CEO and president. Dr. Nedwin joins the company as it accelerates the translation of its microbiome discoveries into a pipeline of clinical opportunities.
Endocyte Appoints President and CEO
Endocyte, a leading developer of targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, has appointed Mike Sherman president and CEO. Mr. Sherman has served as Endocyte’s chief financial officer since 2006 and undertook the additional role of chief operating officer in 2014.
Dr. Burkhard Blank
Acorda Appoints Chief Medical Officer
Acorda Therapeutics has named Burkhard Blank, M.D., chief medical officer. Dr. Blank was appointed as Acorda’s interim CMO in January 2016, and previously served as CMO for several biopharmaceutical companies, including Boehringer Ingelheim.
Dr. Blank’s primary responsibilities include: setting strategy for and execution of development programs from clinical trials through regulatory filings; oversight of postmarketing studies for approved products; and management of the company’s medical affairs, clinical operations, regulatory affairs, drug safety, and biostatistics departments.
Dr. Paul McKenzie
Biogen Names Executive VP, Pharmaceutical Operations & Technology
Biogen has promoted Paul McKenzie, Ph.D., to executive VP, pharmaceutical operations and technology, from his previous position as senior VP of global biologics manufacturing and technical operations.
Dr. McKenzie is leading the organization responsible for asset management, technical development, global manufacturing, supply chain operations, quality, and engineering. He will also oversee construction and operation of Biogen’s advanced biologics manufacturing facility in Solothurn, Switzerland.
Decibel Therapeutics Appoints top exec
Decibel Therapeutics, a hearing company focused on discovering and developing new therapies to protect, repair, and restore hearing, has named industry veteran Steven Holtzman to president and chief executive officer.
Mr. Holtzman succeeds interim CEO Kevin Starr, a partner at Third Rock Ventures, who remains chairman of the board of directors.
Mr. Holtzman joins the company from Biogen, Inc., where he most recently served as executive VP, corporate development.
Iroko Pharmaceuticals Appoints President and CEO
Iroko Pharmaceuticals has named Louis Vollmer president and CEO; he had been serving as president since March 2015. He succeeds Osagie Imasogie, Iroko’s founder, as CEO; Mr. Imasogie remains Iroko’s chairman. Mr. Vollmer is charged with overseeing the day-to-day operations and long-term strategic planning of Iroko, focusing on maximizing the potential of the company’s SoluMatrix franchise brands, expanding the company’s global presence, and creating and acquiring innovative treatment options for responsible pain management.
Dr. Thomas Bramley
Xcenda Names New President
Leading the way in providing additional client services is Xcenda’s new President Thomas Bramley, Ph.D. Dr. Bramley has helped grow the organization from a health economics and outcomes research firm to a global leader in commercialization support. With more than 15 years of experience advising leadership teams in the pharmaceutical industry on real-world evidence generation and market access principles to optimize product success in value-based markets, he is leading Xcenda’s efforts to help manufacturers demonstrate the value of their pharmaceutical products while improving patient access to medications.(PV)